Treatment Information

Back

Liver Cancer treatment details. Biologic therapy.

Karmanos Cancer Institute, Detroit, MI, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Detroit, MI
Treatments:Biologic therapyHospital:Karmanos Cancer Institute
Drugs:Journal:Link
Date:May 2012

Description:

Patients:
This study involved 27 patients with advanced hepatocellular cancer with a median age of 60 years; 74% were male.

Treatment:
Patients were treated with a combination of two biologic therapy agents, bevacizumab and erlotinib (a small molecular inhibitor of epidermal growth factor receptor tyrosine kinase, which is involved in cell growth and survival).

Toxicities:
The maximum grade of treatment-related adverse events was 3 and included fatigue, skin rash, and diarrhea.

Results:
The median overall survival time was 9.5 months.

Support:
Erlotinib was provided by OSI Pharmaceuticals, Inc.

Correspondence: Dr. Philip A. Philip; email: [email protected]



Back